Abstract
In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Infectious Disorders - Drug Targets
Title: Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Volume: 8 Issue: 4
Author(s): Rolando Vernal and Jose A. Garcia-Sanz
Affiliation:
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Abstract: In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Export Options
About this article
Cite this article as:
Vernal Rolando and Garcia-Sanz A. Jose, Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734197
DOI https://dx.doi.org/10.2174/187152608786734197 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Topical Application of <i>In Vitro</i> Transcribed mRNA to the Airways as a Novel Gene Therapy Approach for the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Implementing Central Composite Design for Developing Transdermal Diacerein-Loaded Niosomes: Ex vivo Permeation and In vivo Deposition
Current Drug Delivery HPV Infection and Intraepithelial Lesions: Comparison Between HIVPositive and Negative Women
Current HIV Research Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Translational Molecular Imaging in Drug Development: Current Status and Challenges
Current Medical Imaging Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer
Current Pharmaceutical Design Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets The Use of PET for Radiotherapy
Current Medical Imaging Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues
Protein & Peptide Letters Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents